RE: Synairgen; Act P3, Scene, RNS.16 Jun 2021 07:56
Dibs - Absolutely accurate in your statement, 'It's moving to P3'
Poor Dr Castro working his balls off every day, allowed a little blip in phraseology. One thing I do know. I did not think we would continue on A2 due to HT results. However, I am certain we ARE moving to P3, just a matter of boxes being bureaucratically ticked. The long game has not changed one iota.
Those golden tickets = what you going to do with them …..Mmmmmmmmmm
Holding mine very tightly :-)
Next week will be fun. The endgame is Global P3, lots of dirty big pharma will be scuttling around :-)
Just popping in. I see the BB has been generally quiet with a lot of background 'noise'. This will always remain the situation until news arrives. TBH, I am surprised we are still on A2 after the HT, unless the US have discussed with RM and they see the opportunity in early intervention in 'putting the fire out' in hospitalised patients requiring oxygen, and then letting them go home much earlier to continue their recuperation in the home setting. I have no such doubts about the global P3 - These results WILL once and for all, put SNG on the global stage, probably in a JV/TO venture and shareholders will be wonderfully rewarded. I personally, thought we would see this recent retrace, but did not sell a single share. I cannot take the risk of the exact 'when' news will propel us into the stratosphere, so will just sit back and wait patiently now. I wish all holders a safe and sunny summer.
Tyla - we have all been through the mill and done daft things, you are definitely not alone. Last summer, I bought CINE at 53p, watched them crash to about 27p sold (as thought cinema's were not opening anytime soon) and then watched them go to over £1. Could have beaten myself with a stick :-)
Wish you all the best.
Think we have a little once in a lifetime share on our hands here. 15 years of work already invested by Prof Holgate et al coming to fruition !
Your right, it just gets a better situation for the desperate NEED for an inhaled viral agnostic as each and every day elapses. We all know the science is fantastic and the drug works (think the Verve said that too)
Good work Ferrari
Lots of media attention starting to emanate now around our little company. Think we should prepare for some 'attention'
Enjoy the summer sunshine. Have a great day all :-)
However, the technology is complex, which is why Synairgen has spent 15 years developing the drug. When the pandemic started, the company instantly switched its focus to applying the experimental treatment to Covid.
“We had always recognised that when a scary virus came along that this inhaled interferon beta treatment could help,” said Buzz Marsden !!!!!
I just love the positivity of the various snippets from the Daily Telegraph, just gets better each time I re-read !!!
“And when Covid fizzles out one day we would expect our drug will be given to people hospitalised with influenza and other viruses which trigger an infection in the lungs. That was our ultimate aim, but Covid has condensed five years of work in 18 months.”
In case anyone missed courtesy of Ducati and Mike, thank-you :-)
Synairgen will dose its first patients in India this week with an inhaled drug containing the active ingredient interferon beta By Julia Bradshaw 31 May 2021 • 4:00pm Telegraph Southampton biotech spin-out Synairgen is starting its first Indian variant human trials of a Covid treatment that has proved highly effective in helping patients recover from the virus. The company is dosing its first patients in India this week with an inhaled drug containing the active ingredient interferon beta. It is a protein that the body makes to jolt the immune system into action when it encounters a virus. Covid suppresses the production of this protein, which helps it to evade the immune system. Phase three trials are underway globally and the drug is being tested on several variants, including the Brazilian one. The trial in India is expected to provide data on the treatment’s efficacy against the Indian variant. Richard Marsden, chief executive of Synairgen, said data from earlier trials had been extremely strong. “Our phase two data is the strongest in the world on Covid and if we get the same in phase three it will be transformational for Synairgen,” he said. The company's share price has nearly tripled over the past year as investors pinned their hopes on trial success. Synairgen was founded in 2004 by three academics, professors Donna Davies, Ratko Djukanovic and Sir Stephen Holgate, who still hold shares in the company. Sir Stephen has nearly 900,000 shares that are now valued at £1.4m. The biotech listed in the same year it was created and has been working since then on an inhaled treatment for patients who are hospitalised with severe viral lung infections. The founding professors had seen how people with asthma and other lung conditions often ended up in hospital and were not helped by steroids. They discovered that interferon beta, when inhaled directly into the lung, could offer a new treatment. However, the technology is complex, which is why Synairgen has spent 15 years developing the drug. When the pandemic started, the company instantly switched its focus to applying the experimental treatment to Covid. “We had always recognised that when a scary virus came along that this inhaled interferon beta treatment could help,” said Mr Marsden, who was the first employee hired by Synairgen. “And when Covid fizzles out one day we would expect our drug will be given to people hospitalised with influenza and other viruses which trigger an infection in the lungs. That was our ultimate aim, but Covid has condensed five years of work in 18 months.” The phase three trial started in January and will finish by the second half of this year. If the trials are successful, the drug will be a blockbuster, meaning it could generate annual sales of more than £1bn, and transform the company